Original Research
Accepted on 08 Apr 2025
Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
in Drugs Outcomes Research and Policies